US President Donald Trump signed an executive order requiring pharmaceutical companies to reduce the price of US prescription drugs within 30 days and calling for the implementation of the “Most-Favored-Nation” policy, which means that drug prices paid by Americans must be equal to the lowest prices in the world, which is expected to reduce US drug prices by 30-80%.If the policy is ultimately implemented, it will have a negative impact on all Chinese pharmaceutical and healthcare companies that have operations in the US or have business dealings with US firms, according to Nomura's research report. Related NewsBill Gates: US Ban Expedites CN Chip MfgApart from the potential pricing pressure on innovative drug companies, Chinese CROs providing CRDMO services to pharmaceutical firms selling drugs in the US, as well as Chinese companies licensing clinical-stage assets to multinational firms, may also face pricing pressures.